title: Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.
abstract: BACKGROUND
  The aim of the study was to analyze in breast tumors the correlation between [(18)F]fluorodeoxyglucose (FDG) uptake assessed by positron emission tomography (PET) and histopathological and immunohistochemical prognostic factors.
  
  
  METHODS
  FDG-PET combined with computed tomography (CT) was performed before surgery in 45 women with biopsy-proven primary breast cancer. The standardized uptake value (SUV) was compared with histopathological findings after surgery.
  
  
  RESULTS
  A positive relationship was found between SUV and histological grade (p < 0.0001), histological type (p = 0.001), tumor size (p < 0.0435), estrogen receptor status (p < 0.0005), and progesterone receptor status (p = 0.002). FDG-PET/CT revealed unknown distant metastatic lesions in 2 of 12 patients with triple-negative breast cancer. The sensitivity of FDG-PET/CT for detecting axillary lymph node metastases was, respectively, 21% and 100% for pN1 and pN2 cases, whereas specificity was 100% for pN0.
  
  
  CONCLUSIONS
  SUV, a preoperative and noninvasive metabolic parameter, correlates with other known prognostic factors in breast cancer. This study provides valuable insight into the usefulness of FDG-PET/CT for preoperative staging of patients with triple-negative and poorly differentiated breast tumors but not for evaluating axillary lymph nodes and lobular carcinomas.
authors.affiliation: Department of Medical Oncology, Léon Bérard Cancer Center, 28 Rue Laennec, 69008 Lyon, France. pierreheudel@yahoo.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Heudel
authors.forename: Sebastien
authors.initials: S
authors.lastname: Cimarelli
authors.forename: Anthony
authors.initials: A
authors.lastname: Montella
authors.forename: Catherine
authors.initials: C
authors.lastname: Bouteille
authors.forename: Thomas
authors.initials: T
authors.lastname: Mognetti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D018275:Carcinoma, Lobular / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011300:Preoperative Care; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
references.citation: World J Surg. 2009 May;33(5):943-9
references.pmid: 19259728
references.citation: J Clin Oncol. 2004 Jan 15;22(2):277-85
references.pmid: 14722036
references.citation: Cancer. 2007 May 1;109(9):1721-8
references.pmid: 17387718
references.citation: Q J Nucl Med. 2001 Sep;45(3):257-68
references.pmid: 11788818
references.citation: Ann Surg Oncol. 1994 Mar;1(2):132-40
references.pmid: 7834438
references.citation: Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1317-23
references.pmid: 12271413
references.citation: Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):475-83
references.pmid: 17957366
references.citation: J Nucl Med. 2005 Jul;46(7):1144-50
references.pmid: 16000283
references.citation: J Nucl Med. 1997 Aug;38(8):1186-91
references.pmid: 9255146
references.citation: Br J Surg. 2009 Feb;96(2):166-70
references.pmid: 19160365
references.citation: Clin Positron Imaging. 1999 Oct;2(5):261-271
references.pmid: 14516650
references.citation: J Cancer Res Clin Oncol. 2004 May;130(5):273-8
references.pmid: 14986112
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3628-36
references.pmid: 12202663
references.citation: J Clin Oncol. 2002 Jan 15;20(2):379-87
references.pmid: 11786564
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Nucl Med. 2001 Jan;42(1):9-16
references.pmid: 11197987
references.citation: Ann Oncol. 2007 Mar;18(3):473-8
references.pmid: 17164229
references.citation: Cancer. 1998 Jun 1;82(11):2227-34
references.pmid: 9610703
references.citation: Cancer. 2008 Mar 1;112(5):995-1000
references.pmid: 18098228
references.citation: Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1543-50
references.pmid: 19415270
references.citation: J Clin Oncol. 2000 Oct 15;18(20):3495-502
references.pmid: 11032590